Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 110 of 110 entries
Sorted by: Best Match Show Resources per page
Patients' style of emotional processing moderates the impact of common factors in psychotherapy.

Psychotherapy (Chicago, Ill.)

Brintzinger M, Tschacher W, Endtner K, Bachmann K, Reicherts M, Znoj H, Pfammatter M.
PMID: 34472933
Psychotherapy (Chic). 2021 Dec;58(4):472-484. doi: 10.1037/pst0000370. Epub 2021 Sep 02.

This study examined how patient characteristics concerning processing of emotions interact with common factors in psychotherapy. We focused on common factors of emotional processing in psychotherapy with regard to depression outcome. A total of 93 psychiatric outpatients were included....

Cite
Brintzinger M, Tschacher W, Endtner K, et al. Patients' style of emotional processing moderates the impact of common factors in psychotherapy. Psychotherapy (Chic). 2021;58(4):472-484doi: 10.1037/pst0000370.
Brintzinger, M., Tschacher, W., Endtner, K., Bachmann, K., Reicherts, M., Znoj, H., & Pfammatter, M. (2021). Patients' style of emotional processing moderates the impact of common factors in psychotherapy. Psychotherapy (Chicago, Ill.), 58(4), 472-484. https://doi.org/10.1037/pst0000370
Brintzinger, Miriam, et al. "Patients' style of emotional processing moderates the impact of common factors in psychotherapy." Psychotherapy (Chicago, Ill.) vol. 58,4 (2021): 472-484. doi: https://doi.org/10.1037/pst0000370
Brintzinger M, Tschacher W, Endtner K, Bachmann K, Reicherts M, Znoj H, Pfammatter M. Patients' style of emotional processing moderates the impact of common factors in psychotherapy. Psychotherapy (Chic). 2021 Dec;58(4):472-484. doi: 10.1037/pst0000370. Epub 2021 Sep 02. PMID: 34472933.
Copy Download .nbib Format: NLM
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.

Blood

Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.
PMID: 34758069
Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845.

Observation is the current standard of care for patients with early-stage asymptomatic chronic lymphocytic leukemia (CLL), as chemotherapy-based interventions have failed to prolong survival. We hypothesized that early intervention with ibrutinib would be well tolerated and lead to superior...

Cite
Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022;139(2):177-187doi: 10.1182/blood.2021010845.
Langerbeins, P., Zhang, C., Robrecht, S., Cramer, P., Fürstenau, M., Al-Sawaf, O., von Tresckow, J., Fink, A. M., Kreuzer, K. A., Vehling-Kaiser, U., Tausch, E., Müller, L., Eckart, M. J., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Wendtner, C. M., Fischer, K., Stilgenbauer, S., Eichhorst, B., & Hallek, M. (2022). The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood, 139(2), 177-187. https://doi.org/10.1182/blood.2021010845
Langerbeins, Petra, et al. "The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia." Blood vol. 139,2 (2022): 177-187. doi: https://doi.org/10.1182/blood.2021010845
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845. PMID: 34758069.
Copy Download .nbib Format: NLM
Showing 109 to 110 of 110 entries